Design, synthesis, and biological evaluation of novel aminopyrimidinylisoindolines as AXL kinase inhibitors
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Min Jung | - |
dc.contributor.author | Roh, Eun Joo | - |
dc.contributor.author | Hur, Wooyoung | - |
dc.contributor.author | Lee, So Ha | - |
dc.contributor.author | Sim, Taebo | - |
dc.contributor.author | Oh, Chang-Hyun | - |
dc.contributor.author | Lee, Sun-Hwa | - |
dc.contributor.author | Kim, Jong Seung | - |
dc.contributor.author | Yoo, Kyung Ho | - |
dc.date.accessioned | 2021-09-02T02:08:52Z | - |
dc.date.available | 2021-09-02T02:08:52Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2018-12-15 | - |
dc.identifier.issn | 0960-894X | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/71195 | - |
dc.description.abstract | A novel series of aminopyrimidinylisoindoline derivatives 1a-w having an aminopyrimidine scaffold as a hinge region binding motif were designed and synthesized. Among them, six compounds showed potent inhibitory activities against AXL kinase with IC50 values of submicromolar range. Especially, compound 1u possessing (4-acetylpiperazin-1-yl)phenyl moiety exhibited extremely excellent efficacy (IC50 = < 0.00050 mu M). Their in vitro antiproliferative activities were tested over five cancer cell lines. Most compounds showed good antiproliferative activities against HeLa cell line. The kinase panel profiling of 50 different kinases and the selected inhibitory activities for the representative compound 1u were carried out. The compound 1u exhibited excellent inhibitory activities (IC50 = < 0.00050, 0.025, and 0.050 mu M for AXL, MER, and TYRO3, respectively) against TAM family, together with potent antiproliferative activity against MV4-11 cell line (GI(50) = 0.10 mu M) related to acute myeloid leukemia (AML). | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | PERGAMON-ELSEVIER SCIENCE LTD | - |
dc.subject | RECEPTOR TYROSINE KINASES | - |
dc.subject | TAM FAMILY | - |
dc.subject | CANCER | - |
dc.subject | TARGETS | - |
dc.subject | CELLS | - |
dc.title | Design, synthesis, and biological evaluation of novel aminopyrimidinylisoindolines as AXL kinase inhibitors | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Sim, Taebo | - |
dc.contributor.affiliatedAuthor | Kim, Jong Seung | - |
dc.identifier.doi | 10.1016/j.bmcl.2018.10.013 | - |
dc.identifier.scopusid | 2-s2.0-85054875418 | - |
dc.identifier.wosid | 000453232500033 | - |
dc.identifier.bibliographicCitation | BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, v.28, no.23-24, pp.3761 - 3765 | - |
dc.relation.isPartOf | BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | - |
dc.citation.title | BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | - |
dc.citation.volume | 28 | - |
dc.citation.number | 23-24 | - |
dc.citation.startPage | 3761 | - |
dc.citation.endPage | 3765 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Organic | - |
dc.subject.keywordPlus | RECEPTOR TYROSINE KINASES | - |
dc.subject.keywordPlus | TAM FAMILY | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | TARGETS | - |
dc.subject.keywordPlus | CELLS | - |
dc.subject.keywordAuthor | Aminopyrimidinylisoindolines | - |
dc.subject.keywordAuthor | Inhibitors | - |
dc.subject.keywordAuthor | AXL kinase | - |
dc.subject.keywordAuthor | TAM family | - |
dc.subject.keywordAuthor | Enzyme inhibitory activity | - |
dc.subject.keywordAuthor | Antiproliferative activity | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.